MDWD — Mediwound Income Statement
0.000.00%
- $195.40m
- $159.17m
- $20.22m
- 23
- 10
- 89
- 35
Annual income statement for Mediwound, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 21.8 | 23.8 | 26.5 | 18.7 | 20.2 |
Cost of Revenue | |||||
Gross Profit | 7.54 | 8.77 | 13.2 | 3.58 | 2.63 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 30.6 | 35 | 34.8 | 34 | 39.6 |
Operating Profit | -8.84 | -11.2 | -8.35 | -15.3 | -19.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -9.28 | -13.5 | -19.5 | -6.53 | -30.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -9.28 | -13.6 | -19.6 | -6.72 | -30.2 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -9.2 | -13.6 | -19.6 | -6.72 | -30.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -9.2 | -13.6 | -19.6 | -6.72 | -30.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.39 | -3.48 | -3.81 | -0.76 | -3.03 |